Regular ArticleExpression of Matrix Metalloproteinases and their Inhibitors in Experimental Retinal Ischemia-Reperfusion Injury in Rats
References (29)
A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding
Anal. Biochem.
(1976)- et al.
Retinoid modulate endothelial cell production of matrix-degrading proteases and tissue inhibitor of metalloproteinases (TIMP)
J. Biol. Chem.
(1994) - et al.
Early appearance of activated matrix metalloproteinase 9 and blood brain barrier disruption in mice after focal cerebral ischemia and reperfusion
Brain Res.
(1999) Quantitation of ischemic damage in the rat retina
Exp. Eye Res.
(1991)- et al.
Apoptotic DNA fragmentation and upregulation of Bax induced by transient ischemia of the rat retina
Brain Res.
(1999) - et al.
Quantitative zymography: detection of picogram quantities of gelatinases
Anal. Biochem.
(1994) Metalloproteinase and their inhibitor in matrix remodeling
Trends Genet.
(1990)- et al.
Quantitative reverse zymography: analysis of picogram amounts of metalloproteinase inhibitors using gelatinase A and B reverse zymograms
Anal. Biochem.
(1997) - et al.
Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 in the retinal pigment epithelium and interphotoreceptor matrix: vectorial secretion and regulation
Exp. Eye Res.
(1997) - et al.
Polarized distribution of metalloproteinases in the bovine interphotoreceptor matrix
Exp. Eye Res.
(1994)
Blood-retinal barrier breakdown following experimental retinal ischemia and reperfusion
Exp. Eye Res.
Retina neovascularization is suppressed with a matrix metalloproteinase inhibitor
Arch. Ophthalmol.
Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue
FASEB J.
Early appearance of activated matrix metoprotinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier disfunction
J. Cereb. Blood Flow Metab.
Cited by (51)
Involvement of matrix metalloproteinases in capillary degeneration following NMDA-induced neurotoxicity in the neonatal rat retina
2019, Experimental Eye ResearchCitation Excerpt :Activation of MMPs is a common characteristic of many diseases, including neurodegenerative disorders such as glaucoma (Guo et al., 2005; De Groef et al., 2014; Zalewska et al., 2016). In rodent models of retinal degeneration, increased expression and activity of MMP-9 in the retina promote death of RGCs (Chintala et al., 2002; Zhang et al., 2002, 2004; Zhang and Chintala, 2004; Guo et al., 2005; Mali et al., 2005; Manabe et al., 2005; Mathalone et al., 2007). MMP-9 degrades laminin and changes the structure of ECM, thus contributing to neuronal degeneration by a form of apoptosis known as anoikis (Chintala et al., 2002; Zhang et al., 2004).
A role of PSA-NCAM in the survival of retinal ganglion cells (RGCs) after kainic acid damage
2019, NeuroToxicologyCitation Excerpt :MMPs belong to the zinc proteases superfamily and specialize in degrading the extracellular matrix, cytokines, growth factors, cell surface receptors, and cell adhesion molecules (Bonnans et al., 2014; Rodriguez et al., 2010). MMPs show low expression and activity in normal conditions but are increased during remodelling or repair and in disease, such as diabetic retinopathy (Kowluru et al., 2014), glaucoma (De Groef et al., 2014), retina ischemia (Zhang et al., 2002). Activated astroglia and Müller cells are the major sources of MMP-9 protein (Zhang et al., 2004b).
Role of diagnostic factors associated with antioxidative status and expression of matrix metalloproteinases (MMPs) in patients with cancer therapy induced ocular disorders
2018, Saudi Journal of Biological SciencesCitation Excerpt :and downregulated levels of TIMP1 and TIMP2 were detected in both cancer and cataract patients (Määttä et al., 2006). It has been demonstrated that the higher quantity of MMP-9 was examined in both posterior and anterior segments of eye after experimentally induced retinal reperfusion injury but the levels of TIMP 1 and 2 remained unchanged (Zhang et al., 2002). Thus, use of TIMP 1 & 2 or MMP-9 inhibitors can prevent corneal injuries.
Neutralization of IL-23 depresses experimental ocular neovascularization
2016, Experimental Eye ResearchMMP-9 inhibition facilitates amacrine cell loss after ouabain-induced retinal damage
2015, Experimental Eye ResearchCitation Excerpt :The pathological activation of MMPs, in particular MMP-9, has been associated with neuronal degeneration and brain damage in ischemic stroke (Gu et al., 2002, 2005; Lee et al., 2004), traumatic brain injury (TBI) (Hadass et al., 2013; Zhang et al., 2010) and intracerebral hemorrhage (ICH) (Grossetete and Rosenberg, 2008; Tang et al., 2004; Xue et al., 2006). Retinal ischemia caused by optic nerve ligation (Chintala, 2002; Zhang et al., 2002; Zhang and Chintala, 2004; Zhang et al., 2004a), the elevation of intraocular pressure (Guo et al., 2005; Mathalone et al., 2007) and application of membrane-depolarizing potassium chloride (KCL) (Mali et al., 2005), excitotoxic NMDA (Manabe et al., 2005) and KA (Zhang et al., 2004b) has been shown to increase MMP-9 expression and activation in rats or mice. Synthetic inhibitors of MMPs or a deficiency in MMP-9 in the retinas have been shown to protect against RGCs loss and the reduction of laminin in the inner limiting membrane of the retina, suggesting that MMP-9 promotes the death of RGCs by degrading the laminin and changing the ECM (Chintala, 2002; Mali et al., 2005; Manabe et al., 2005; Zhang et al., 2004b).
Comparison of interleukin-6 and matrix metalloproteinase expression in the subretinal fluid and the vitreous during proliferative vitreoretinopathy: Correlations with extent, duration of RRD and PVR grade
2014, CytokineCitation Excerpt :The diverse MMP functionality is apparent during RRD. Collagenases (such as MMP-1) and stromelysins have been reported to be expressed at the onset of RRD and are associated with increased matrix degradation [23]. Increased MMP-9 activity has been associated with acute pathological circumstances and also appears to be implicated in PVR pathophysiology [18].
- f1
Address correspondence to: Taiji Sakamoto, Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. E-mail: [email protected]